Abstract Body

Mycobacteria tuberculosis kills more people every year than any other single pathogen, yet the first-line treatment regimen used globally has remained largely unchanged for 40 years. Shorter, safer, and more effective regimens are urgently needed to halt the epidemic. Clinical trials for new drugs to treat HIV depend on changes in HIV viral load as an established marker of infection and treatment response. In contrast, while several new TB drugs are in clinical development, the absence of a reliable surrogate endpoint hampers decisions about whether and when a new TB regimen is ready for confirmatory phase III evaluation. Further challenges include the necessity of determining the optimal combination and duration of therapy during phase II development alongside the limited funding for TB drug development and the allure of accelerated approval. In this workshop, I will talk about the burden of expectations and the latest developments in designing phase II trials to identify the best regimens to advance to phase III. I will talk about platform and other adaptive treatment-selection trial designs, the novel phase IIC design, designs to identify the optimal duration of therapy and the role of an internal control. I will also touch on challenges in TB prevention trials in the absence of a true marker of infection.